Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry-Guided Breathing Therapy - Phase 2
Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry Guided Breathing Therapy - Phase 2
The purpose of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of two early interventions, Written Exposure Therapy (WET) and Capnometry-Guided Breathing Intervention (CGRI), for reducing post-traumatic stress disorder (PTSD) symptoms following childbirth, compared with usual care.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- University of Arkansas for Medical Sciences
-
Kontakt:
- Heather Moody
- Telefonnummer: 501-526-4333
- E-Mail: HLMoody@uams.edu
-
-
California
-
Palo Alto, California, Vereinigte Staaten, 94304
- Stanford University
-
Kontakt:
- Guillermina Ferrea
- Telefonnummer: (650) 457 7704
- E-Mail: gferrea@stanford.edu
-
Kontakt:
- Aleesha Jethwa
- Telefonnummer: +44 7857 907762
- E-Mail: Ajethwa1@stanford.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥18
- Delivered a live infant within 5 days
- Severe maternal morbidity or infant admitted to NICU
- PCL-5 ≥28
- English-speaking
- Able to consent and participate
Exclusion Criteria:
- Active psychosis or mania
- Current suicidal crisis
- Current suicidal intent or plan
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Written Exposure Therapy (WET)
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
|
Experimental: Capnometry-Guided Breathing Intervention (CGRI)
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
|
Kein Eingriff: Postpartum Standard of Care
Participants will follow their current standard of care. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Prozentsatz der Teilnehmer, die die Schreibbasierte Expositionstherapie (WET) abschließen
Zeitfenster: Baseline bis Woche 6
|
Baseline bis Woche 6
|
|
|
Prozentuale Adhärenz zur Written Exposure Therapy (WET)
Zeitfenster: Baseline bis Woche 6
|
Baseline bis Woche 6
|
|
|
Prozentsatz der Teilnehmer, die die kapnometriegeführte Atemintervention (CGRI) abschließen
Zeitfenster: Baseline bis Woche 6
|
Baseline bis Woche 6
|
|
|
Prozentuale Einhaltung der kapnometriegeführten Atemintervention (CGRI)
Zeitfenster: Baseline bis Woche 6
|
Baseline bis Woche 6
|
|
|
Percentage of participants initiating assigned treatment
Zeitfenster: Baseline (up to 2 weeks)
|
Proportion of participants who begin their assigned intervention (≥1 session for WET; completion of initial training for CGRI) |
Baseline (up to 2 weeks)
|
|
Participant Satisfaction Scale Score using Client Satisfaction Questionnaire (CSQ-8)
Zeitfenster: Week 5
|
Participant satisfaction measured using the CSQ-8 questionaire, an 8-item scale. (Scale score 8 - 32. Higher scores represent greater satisfaction with treatment.) |
Week 5
|
|
Treatment credibility using the Opinion About Treatment (OAT) form
Zeitfenster: Week 5
|
Participant perceptions of treatment credibility will be measured using the OAT form. (Scale score 3 - 27. Higher scores represent greater perceived credibility of the intervention.) |
Week 5
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from baseline in PTSD Checklist for DSM-5 (PCL-5) Scale Score
Zeitfenster: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Change in PTSD symptoms during past week measured by the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure. (Score range 0 - 80, higher scores indicating greater severity of PTSD symptoms.). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) Scale Score
Zeitfenster: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Participants complete the EPDS questionnaire, a 10-item scale assessing postpartum depressive symptoms over the past 7 days. (Score range 0 - 30, higher scores represents greater symptom severity.) |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Whole Person Health Index (WPHI) Scale Score
Zeitfenster: Baseline, Week 3, Week 6, Week 12
|
Participants complete WHPI questionaire, a 9 item scale assessing global health and functioning. (Score range 9 - 81, higher scores represent better health). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Generalized Anxiety Disorder Questionaire (GAD-7)
Zeitfenster: Baseline, Week 3, Week 6, Week 12
|
Participants complete the GAD-7, a 7-item scale assessing anxiety symptoms over 2 weeks. (Score range 0 - 21, higher scores represent greater anxiety severity.) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Maternal-infant bonding (MIBS) Scale Score
Zeitfenster: Baseline, Week 3, Week 6, Week 12
|
Participants complete the MIBS questionaire, an 8 item measure of bonding difficulties over the past few weeks (Score range 0 - 24, higher scores represent greater bonding impairment). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in STanford Obstetric Recovery checKlist (STORK) scale score
Zeitfenster: Baseline, Week 3, Week 6, Week 12
|
Participants complete the STORK questionnaire, a 47-item scale assessing postpartum recovery over the past 7 days. (Score range 0 - 188, higher score represents a greater degree of recovery) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Breastfeeding Self-Efficacy Scale-Short Form (BFSES-SF)
Zeitfenster: Baseline, Week 3, Week 6, Week 12
|
Participants complete the BFSES-SF, a 14-item measure of breastfeeding self-efficacy (Score range 14 - 70, higher scores indicate greater breastfeeding confidence.) |
Baseline, Week 3, Week 6, Week 12
|
|
Percentage of participants completing hair sample collection at Baseline and Week 6
Zeitfenster: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. |
Baseline, Week 6
|
|
Change in hair cortisol concentration between Baseline and Week 6
Zeitfenster: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisol concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair cortisone concentration between Baseline and Week 6
Zeitfenster: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair testosterone concentration between Baseline and Week 6
Zeitfenster: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair testosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair progesterone concentration between Baseline and Week 6
Zeitfenster: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair progesterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair corticosterone concentration between Baseline and Week 6
Zeitfenster: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair corticosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair dehydroepiandrosterone (DHEA) concentration between Baseline and Week 6
Zeitfenster: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair dehydroepiandrosterone (DHEA) concentration values from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair androstenedione concentration between Baseline and Week 6
Zeitfenster: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair androstenedione concentration from Baseline to Week 6 |
Baseline, Week 6
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Pervez Sultan, Stanford University
- Hauptermittler: Debra Kaysen, Stanford University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 80498-2
- R01AT013866-01 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD-Sharing-Zeitrahmen
Beginning 9 months and ending 36 months following article publication.
IPD-Sharing-Zugriffskriterien
Wish whom? Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For what types of analysis? For individual participant data meta-analysis By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .